Dianthus Therapeutics, Inc. (DNTH) Stock Analysis

Q: What is the DNTH stock price target?

Take-profit $109.15 (+26.7% upside). Prior stop was $80.13.

Q: What are the risks of investing in DNTH?

Concentration risk — Product: claseprubart; Quality below floor (3.0 < 4.0); Quality below floor (3.0 < 4.0); Momentum score 2.5/10 — below 4.5 minimum.

Q: Is DNTH overvalued or undervalued?

Dianthus Therapeutics, Inc. trades at a P/E of N/A (forward -16.3). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about DNTH?

22 analysts cover DNTH with a consensus score of 4.4/5. Average price target: $125.

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Dianthus Therapeutics is a clinical-stage biotech developing claseprubart (anti-C1s monoclonal antibody for gMG, CIDP, MMN) and DNTH212 (bifunctional for autoimmune diseases). Phase 3 CAPTIVATE trial in CIDP showed early positive interim results in March 2026; Phase 3 in gMG... Read more

$86.17+26.7% A.UpsideScore 5.0/10#76 of 158 Biotechnology

Stop $80.13Target $109.15(analyst − 13%)A.R:R 3.1:1

Analyst target$125.46+45.6%13 analysts

$109.15our TP

$86.17price

$125.46mean

$200

Sell if holding. Engine safety override at $86.17: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 4.64; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Product: claseprubart

Quality below floor (3.0 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-16.3

Mkt Cap$4.5B

EV/EBITDA-18.6

Profit Mgn0.0%

ROE-38.4%

Rev Growth-78.6%

Beta0.21

DividendNone

Rating analysts22

Quality Signals

Piotroski F4/9

Options Flow

P/C4.64bearish

IV66%elevated

Max Pain$20-76.8% vs spot

Concentration Risks(10-K Item 1A)

HIGHProductclaseprubart
10-K Item 1A: 'We are substantially dependent on the success of our most advanced product candidate, claseprubart'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality3.015%0.45

Growth5.015%0.75

Momentum2.510%0.25

Sentiment7.910%0.79

Insider Activity3.010%0.30

Peer Rank4.510%0.45

Technical Setup7.45%0.37

Risk Profile4.25%0.21

Catalyst2.55%0.13

Overall (Σ contributions)5.04

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Volume

0.0

Obv

1.0

Rsi

5.5

Ma Position

6.0

Volume distribution (falling OBV)Above 200-day MA

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 0B/4MEarnings in 11 days

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Net Margin

0.0

Fcf Quality

0.0

Rule Of 40

3.0

Piotroski F

4.4

Current Ratio

5.0

Moat

5.0

Gross Margin

10.0

Cash-burning: FCF -3706% of revenueNo competitive moatRule of 40: -3784 (fail)

GatesMomentum 2.5<4.5EARNINGS PROXIMITY 11d<=14d (soft)A.R:R 3.1 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

42 · Neutral

↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $81.81Resistance $96.50

Price Targets

$80

$109

A.Upside+26.7%

A.R:R3.1:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (3.0 < 4.0)

! Momentum score 2.5/10 — below 4.5 minimum

Earnings

0/4 beats

Next Earnings2026-05-11 (11d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is DNTH stock a buy right now?

Sell if holding. Engine safety override at $86.17: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 4.64; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $80.13. Score 5.0/10, moderate confidence.

What is the DNTH stock price target?

Take-profit target: $109.15 (+26.7% upside). Prior stop was $80.13. Stop-loss: $80.13.

What are the risks of investing in DNTH?

Concentration risk — Product: claseprubart; Quality below floor (3.0 < 4.0).

Is DNTH overvalued or undervalued?

Dianthus Therapeutics, Inc. trades at a P/E of N/A (forward -16.3). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about DNTH?

22 analysts cover DNTH with a consensus score of 4.4/5. Average price target: $125.

What does Dianthus Therapeutics, Inc. do?Dianthus Therapeutics is a clinical-stage biotech developing claseprubart (anti-C1s monoclonal antibody for gMG, CIDP,...